Navigation Links
The Neuropathy Association's Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
Date:11/10/2008

NEW YORK, Nov. 10 /PRNewswire-USNewswire/ -- The Neuropathy Association has announced two awardees for its annual Scientific Research Grants Program.

Every year, The Neuropathy Association--a national patient-based non-profit organization dedicated to finding a cure for neuropathy--awards two scientific research grants, each for $80,000 over a two-year period.

This year's grant recipients--Gary J. Bennett, Ph.D. of McGill University (Quebec, Canada) and Helene Bour-Jordan, Ph.D. and co-principal investigator, Mark S. Anderson, M.D., Ph.D. of the University of California, San Francisco (UCSF) Diabetes Center--were chosen from eleven applicants involved in neuropathy research at medical institutions across North America.

Dr. Bennett's proposal, Mechanism of Paclitaxel-Evoked Peripheral Neuropathy, is based on data suggesting that paclitaxel (Taxol(R)) causes neuropathy by a novel and previously unrecognized mechanism. Paclitaxel is used by tens of thousands of patients as a first-line drug in the treatment of ovarian, breast and non-small cell lung cancer. The neuropathy, a serious side-effect of paclitaxel, can be severe---and often painful---thus preventing or limiting the use of the drug as an effective chemotherapeutic and leading to a decline in the patient's quality of life.

Dr. Bennett adds, "Preventing and controlling the neuropathy resulting from paclitaxel will, in turn, allow us to administer larger doses to more effectively kill cancer cells and save lives."

With their proposal, Identification of Neural Autoantigens in Autoimmune Peripheral Neuropathy, Drs. Bour-Jordan and Anderson hope to identify proteins of the peripheral nervous system that are targeted by the immune system in autoimmune neuropathy.

Dr. Bour-Jordan explains, "Autoantibodies in tissue-specific autoimmune diseases are excellent indicators of disease and are instrumental in identifying major autoantigens that are now used in clinical trials
'/>"/>

SOURCE The Neuropathy Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
2. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
3. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
4. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
5. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
6. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
7. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
8. Pharmacist Associations Partner to Increase the Voice of Pharmacy
9. Major Associations Band Together to Urge Congressional Action on Tobacco Legislation
10. American Heart Associations Announces Call for Entries for Howard L. Lewis Achievement Award
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... CA (PRWEB) August 31, 2014 Kicking ... kicking coach Matt Nelson of Matt Nelson Kicking Academy ... business, and on being a National Camp Series (NCS) ... of HustedKicking.com. , "Matt Nelson is another high quality ... many attributes to coaching. He is an outstanding ...
(Date:8/31/2014)... August 31, 2014 This September, ... California State Library, celebrates 30 years of changing ... Since its inception, California’s Library Literacy Services has ... learn to read and write. , To mark ... the state is launching a month-long awareness campaign ...
(Date:8/31/2014)... 2014 With the NCAA set to ... hosted an interview with Yale University Associate Athletic Director ... Yale’s approach to ensuring student-athlete experience that is consistent ... highlighted a number of key factors that contribute to ... critical factor in creating this culture seems simple at ...
(Date:8/31/2014)... 31 August 2014: Renal denervation seems to be more ... hypertension when it includes accessory renal arteries, according to ... Schmiedel from Germany. , Dr Schmiedel said: "More than ... is defined as blood pressure (BP) greater than 140/90 ... hypertension (rHTN) and are unable to reduce BP below ...
(Date:8/31/2014)... Barcelona, Spain Sunday 31 August 2014: Drinking tea ... 131 000 people presented at ESC Congress today by ... "If you have to choose between tea or coffee ... are important components of our way of life. Their ... the past with sometimes divergent results. We investigated the ...
Breaking Medicine News(10 mins):Health News:MichaelHusted.com Features an Interview with Matt Nelson of Matt Nelson Kicking Academy on His Role as a Kicking Coach and on Becoming a National Camp Series Associate 2Health News:MichaelHusted.com Features an Interview with Matt Nelson of Matt Nelson Kicking Academy on His Role as a Kicking Coach and on Becoming a National Camp Series Associate 3Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 2Health News:Yale University’s Steve Conn Discusses NCAA Football, Student-Athlete Experience, & Social Media SCI Talk Interview 3Health News:Renal denervation more successful when it includes accessory arteries 2Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3
... ARLINGTON, Va., Nov. 16 Acknowledging that their results ... in the International Journal of Andrology nevertheless attempt to link ... to maternal exposure to phthalates. The researchers, led by ... previous, and much publicized, study of phthalate exposure to evaluate ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... Company will hold a teleconference and webcast at 8:00 a.m. Eastern ... Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of ... Conference Call and Webcast Information , To participate ...
... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
... ... its intention to begin the drug registration process in Brazil and Colombia for its ... United States for the treatment of moderate to severe (Stage 2) chronic pain. ... Plantation, FL (Vocus) ...
... , ... from the RecordAF,registry (REgistry on Cardiac rhythm disORDers assessing ... Sessions of the,American Heart Association, show that in recently ... rhythm-control strategy,provides better short term control of the arrhythmia ...
... when new lead is needed in heart devices, ... -- Replacing or adding wiring increases the risk ... replace a pacemaker or other heart rhythm-stabilizing device, ... complication rates among patients enrolled in the REPLACE ...
Cached Medicine News:Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 2Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 3Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 5
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP has ... or the "Company") (NASDAQ: EDAP ) and ... United States District Court, Southern District of ... on behalf of a class consisting of all persons ... 2013 and July 30, 2014, inclusive (the "Class Period"). This ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Calif., April 8, 2011 Amgen (NASDAQ: ... the expansion of its operations in Brazil, including the ... has also agreed to reacquire rights in Brazil to ... acquired by Hypermarcas). Together, these transactions will provide Amgen ...
... the leading health care supply contracting company, announced today ... to its portfolio of agreements for Cardiac Rhythm Management ... leading provider of medical devices which treat cardiac, neurological ... portfolio of arrhythmia management products, including pacemakers, implantable cardioverter ...
Cached Medicine Technology:Amgen Establishes Commercial Operations in Brazil 2Amgen Establishes Commercial Operations in Brazil 3Amgen Establishes Commercial Operations in Brazil 4Novation Announces the Addition of St. Jude Medical to the Cardiac Rhythm Management Products Portfolio 2
Bambi database allows images, analytical results, and eyebank or clinical information to be stored in an easy-to-access database. In most cases, the analytical results from any of our analysis progra...
This computerized retail software is aimed for opticians/optometrists, optical chains/1 hr superstores, optical HMOs, and ophthalmology groups....
... marketing software enables the efficient capture of ... also has many built-in time saving and ... of name fields and numerous user definable ... data input. The pre-defined options in the ...
... management software for eyecare professionals- ... multi-tasking, multi-office practice management system, ... technology- Winx Pro is a ... you in effectively managing the ...
Medicine Products: